Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol

Expert Opinion on Drug Safety

Volumn 16, Issue 2, 2017, Pages 125-132

  Rolland, Benjamin ^a,b   Auffret, Marine ^b   Labreuche, Julien ^b   Lapeyre Mestre, Maryse ^c   Dib, Malek ^b   Kemkem, Aomar ^b   Grit, Isabelle ^b   Drelon, Marie ^b   Duhamel, Alain ^b,d   Cabe, Nicolas ^e   Vabret, François ^e   Guillin, Olivier ^f   Baguet, Alexandre ^f   Masquelier, Céline ^b   Dervaux, Alain ^g   Deheul, Sylvie ^b   Bordet, Régis ^a,b   Carton, Louise ^a   Cottencin, Olivier ^b,h   Jardri, Renaud ^b,h   Gautier, Sophie ^a,b   more..

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c NS Park FCRIN Network and NeuroToul Center of Excellence for Neurodegenerative Disorders   (France)

^d Faculté de Médecine Pôle Recherché   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h Univ Lille   (France)

Author keywords

adverse drug reaction reporting systems; alcoholism; Baclofen; causality; drug related side effects and adverse reactions; off label use; patient safety; pharmacovigilance; telephone

Indexed keywords

BACLOFEN; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT;

ADULT; ALCOHOL USE IDENTIFICATION TEST; ALCOHOLISM; ARTICLE; CAUSALITY; COHORT ANALYSIS; DISEASE SEVERITY ASSESSMENT; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL DISEASE ASSESSMENT; MULTICENTER STUDY; PROSPECTIVE STUDY; SEDATION; SEVERITY OF ALCOHOL DEPENDENCE QUESTIONNAIRE; SUBSTANCE USE; TELEPHONE; TELEPHONE INTERVIEW; ALGORITHM; CLINICAL TRIAL; DRINKING BEHAVIOR; FRANCE; OFF LABEL DRUG USE; PREVENTION AND CONTROL; PROCEDURES; QUESTIONNAIRE;

ALCOHOL DRINKING; ALCOHOLISM; ALGORITHMS; BACLOFEN; COHORT STUDIES; DRUG MONITORING; FOLLOW-UP STUDIES; FRANCE; GABA-B RECEPTOR AGONISTS; HUMANS; OFF-LABEL USE; PROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; TELEPHONE;

EID: 85006867189     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1270939     Document Type: Article

References (40)

1. Sachais BA, Logue JN, Carey MS., Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol. 1977;34(7):422–428.
2. Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Baclofène:Résumé des caractéristiques du produit [Baclofen:Summary of product characteristics]; [cited 2016 May10]. Available from: http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0232890.htm
3. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake:a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37(5):504–508.
4. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis:randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–1922.
5. Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence:a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34(11):1849–1857.
6. Ponizovsky AM, Rosca P, Aronovich E, et al. Baclofen as add-on to standard psychosocial treatment for alcohol dependence:a randomized, double-blind, placebo-controlled trial with 1year follow-up. J Subst Abuse Treat. 2015;52:24–30.
7. Mirijello A, Caputo F, Vassallo G, et al. GABAB agonists for the treatment of alcohol use disorder. Curr Pharm Des. 2015;21(23):3367–3372.• Most recent review on baclofen for AUD.
8. Rolland B, Bordet R, Cottencin O. Alcohol-dependence:the current French craze for baclofen. Addiction. 2012;107(4):848–849.
9. Dupouy J, Fournier J-P, Jouanjus E, et al. Baclofen for alcohol dependence in France:incidence of treated patients and prescription patterns-A cohort study. Eur Neuropsychopharmacol. 2014;24(2):192–199.
10. Rolland B, Paille F, Fleury B, et al. Off-label baclofen prescribing practices among French alcohol specialists:results of a national online survey. Plos One. 2014;9(6):e98062.
11. BACLOVILLE study (NCT01604330). Baclofen for the Treatment of Alcohol Drinkers - Full Text View - ClinicalTrials.gov; [cited 2016 May10]. Available from: http://clinicaltrials.gov/ct2/show/NCT01604330
12. ALPADIR study (NCT01738282). Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients; [cited 2016 May10]. Available from: http://clinicaltrials.gov/show/NCT01738282
13. Emmerich J, Dumarcet N, Lorence A. France’s new framework for regulating off-label drug use. N Engl J Med. 2012;367(14):1279–1281.
14. Rolland B, Labreuche J, Duhamel A, et al. Baclofen for alcohol dependence:relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. 2015;25(10):1631–1636.
15. Rolland B, Deheul S, Danel T, et al. A case of De novo seizures following a probable interaction of high-dose baclofen with alcohol. Alcohol Alcohol. 2012;47(5):577–580.
16. Franchitto N, Pelissier F, Lauque D, et al. Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness:an emergency department case series. Alcohol Alcohol. 2014;49(1):79–83.
17. Pape E, Roman E, Scala-Bertola J, et al. Death of an alcohol-dependent patient following intentional drug intoxication:implication of baclofen? Eur Addict Res. 2014;20(6):300–304.
18. Auffret M, Rolland B, Deheul S, et al. Severe tinnitus induced by off-label baclofen. Ann Pharmacother. 2014;48(5):656–659.
19. Bence C, Cottencin O, Deheul S, et al. Baclofen-induced edema in alcohol use disorders. J Clin Pharmacol. 2014;54(4):478–481.
20. Macaigne G, Champagnon N, Harnois F, et al. Baclofen-induced acute hepatitis in alcohol-dependent patient. Clin Res Hepatol Gastroenterol. 2011;35(5):420–421.
21. Villier C, Schir E, Mallaret M, Effets indésirables du baclofène dans le traitement des addictions Suivi national de Pharmacovigilance [Internet]. Comité technique de Pharmacovigilance; 2012 [cited 2016 May10]. Available from: http://ansm.sante.fr/…/2/…/baclofene–suivi-pharmacovigilance-2011.pdf
22. Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Rapport du Comité Technique de Pharmacovigilance [Report of the Pharmacovigilance Technical Committee]; [cited 2016 May10]. Available from: http://ansm.sante.fr/content/download/52485/676187/version/2/file/CR_CT012013023_Pharmacovigilance.pdf
23. Rolland B, Auffret M, Franchitto N. Safety reports on the off-label use of baclofen for alcohol-dependence:recommendations to improve causality assessment. Expert Opin Drug Saf. 2016;1–5. DOI:10.1517/14740338.2016.1168397.•• Comprehensive review on previously-published safety reports on baclofen for AUD.
24. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration:guidance for protocols of clinical trials. Bmj. 2013;346:e7586.
25. Sobell LC, Sobell MB, Leo GI, et al. Reliability of a timeline method:assessing normal drinkers’ reports of recent drinking and a comparative evaluation across several populations. Br J Addict. 1988;83(4):393–402.
26. Stockwell T, Murphy D, Hodgson R. The severity of alcohol dependence questionnaire:its use, reliability and validity. Br J Addict. 1983;78(2):145–155.
27. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT):WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction. 1993;88(6):791–804.
28. Brooks J, Baker GA, Aldenkamp AP. The A-B neuropsychological assessment schedule (ABNAS):the further refinement of a patient-based scale of patient-perceived cognitive functioning. Epilepsy Res. 2001;43(3):227–237.
29. Food and Drug Administration. What is a Serious Adverse Event? [cited 2016 May10]. Available from: http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm
30. Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Thérapie. 1985;40(2):111–118.
31. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
32. Machin D, Cheung YB, Parmar M. Survival analysis:a practical approach. New york:John Wiley & Sons; 2006. p. 281.
33. Sobell LC, Brown J, Leo GI, et al. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend. 1996;42(1):49–54.
34. Stockwell T, Murphy D, Hodgson R. The severity of alcohol dependence questionnaire:its use, reliability and validity. Br J Addict. 1983;78(2):145–155.
35. Gache P, Michaud P, Landry U, et al. The Alcohol Use Disorders Identification Test (AUDIT) as a screening tool for excessive drinking in primary care:reliability and validity of a French version. Alcohol Clin Exp Res. 2005;29(11):2001–2007.
36. Prentice RL, Kalbfleisch JD, Peterson AV, Jr, et al. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541–554.
37. Rolland B, Mann K, Paille F, et al. The New French guidelines on alcohol misuse:an initiative for strengthening cross-European interplay. Addiction. 2015;110(8):1362–1363.
38. Rolland B, Paille F, Gillet C, et al. Pharmacotherapy for alcohol-dependence:the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther. 2016;22(1):25–37.• Explains how baclofen is officially recommended for use for AUD in France.
39. Müller CA, Geisel O, Pelz P, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study):A randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015;25(8):1167–1177.
40. Rolland B, Valin T, Langlois C, et al. Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen:a comparative cohort study. Int Clin Psychopharmacol. 2015;30(1):49–53.